
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) – Stock analysts at HC Wainwright cut their FY2026 earnings estimates for 4D Molecular Therapeutics in a research note issued to investors on Monday, November 16th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings of ($4.20) per share for the year, down from their prior forecast of ($4.08). HC Wainwright currently has a “Buy” rating and a $36.00 target price on the stock. The consensus estimate for 4D Molecular Therapeutics’ current full-year earnings is ($4.21) per share. HC Wainwright also issued estimates for 4D Molecular Therapeutics’ Q4 2026 earnings at ($1.07) EPS, FY2027 earnings at ($4.43) EPS, FY2028 earnings at ($4.74) EPS, FY2029 earnings at ($3.58) EPS and FY2030 earnings at ($1.75) EPS.
Other equities analysts also recently issued reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Thursday, October 15th. B. Riley Financial restated a “buy” rating on shares of 4D Molecular Therapeutics in a report on Monday, August 17th. Citigroup reaffirmed a “buy” rating on shares of 4D Molecular Therapeutics in a research report on Thursday, October 22nd. Bank of America upped their target price on 4D Molecular Therapeutics from $29.00 to $33.00 and gave the stock a “buy” rating in a report on Tuesday, September 29th. Finally, The Goldman Sachs Group reiterated a “buy” rating and set a $32.00 target price on shares of 4D Molecular Therapeutics in a report on Thursday, August 13th. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, 4D Molecular Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $30.22.
4D Molecular Therapeutics Stock Up 2.5%
Shares of FDMT stock opened at $10.72 on Wednesday. The firm’s fifty day moving average price is $12.86 and its two-hundred day moving average price is $11.11. The company has a current ratio of 6.15, a quick ratio of 6.15 and a debt-to-equity ratio of 0.06. 4D Molecular Therapeutics has a 1 year low of $6.96 and a 1 year high of $16.93. The firm has a market capitalization of $604.39 million, a P/E ratio of -3.97 and a beta of 2.92.
4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.03). 4D Molecular Therapeutics had a negative net margin of 208.57% and a negative return on equity of 47.06%. The business had revenue of $4.14 million during the quarter, compared to the consensus estimate of $4.13 million.
Insider Buying and Selling at 4D Molecular Therapeutics
In related news, insider David Kirn sold 58,333 shares of the business’s stock in a transaction on Monday, October 5th. The shares were sold at an average price of $12.92, for a total transaction of $753,662.36. Following the transaction, the insider directly owned 709,153 shares in the company, valued at approximately $9,162,256.76. The trade was a 7.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 120,520 shares of company stock valued at $1,615,978 over the last three months. 7.90% of the stock is currently owned by company insiders.
Institutional Trading of 4D Molecular Therapeutics
A number of large investors have recently added to or reduced their stakes in the company. Jupiter Topco LLC acquired a new position in 4D Molecular Therapeutics during the second quarter worth approximately $76,466,000. BlackRock Inc. bought a new stake in 4D Molecular Therapeutics in the second quarter valued at approximately $60,463,000. Janus Henderson Group PLC raised its stake in 4D Molecular Therapeutics by 13.2% in the first quarter. Janus Henderson Group PLC now owns 5,247,151 shares of the company’s stock valued at $48,868,000 after buying an additional 611,276 shares during the period. Trails Edge Capital Partners LP acquired a new stake in shares of 4D Molecular Therapeutics in the second quarter valued at approximately $29,631,296. Finally, Bank of America Corp DE acquired a new stake in shares of 4D Molecular Therapeutics in the second quarter valued at approximately $14,905,000. Institutional investors and hedge funds own 99.27% of the company’s stock.
4D Molecular Therapeutics Company Profile
4D Molecular Therapeutics, Inc. is a biotechnology company developing genetic medicines for serious diseases. Its research focuses on adeno-associated virus (AAV) gene therapies, which use engineered viral vectors to deliver therapeutic genetic material to cells. The company’s proprietary Therapeutic Vector Evolution platform is designed to create AAV vectors with targeted properties, including the ability to reach specific tissues. Its investigational programs have included treatments for retinal diseases, cystic fibrosis and Fabry disease.
Featured Articles
- Five stocks we like better than 4D Molecular Therapeutics
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
